SynthesisBMC cancer2019

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.

Shanshan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.